呵呵_老虎社区_美港股上老虎 - 老虎社区

点赞
评论
收藏

吴富暴富
2021-07-21

呵呵

高盛首予科济药业-B(02171.HK)「买入」评级目标价48.72元

高盛发表研究报告，首予科济药业-B 「买入」评级，目标价48.72元。该行称，公司是临床阶段生科企业，专注於实质固态瘤及血液科恶性疾病的创新嵌合抗原受体(CAR-T)细胞疗法。该行相信科济药业将是CAR-T行业领导，旗下CLDN 18.2-目标CAR-T CT041有潜在成为全球同类第一(FIC)，具良好胃癌早期临床数据；以及全球专利有重大海外商业机遇。(da/a)~阿思达克财经新闻网址: www.aastocks.com

高盛首予科济药业-B(02171.HK)「买入」评级目标价48.72元

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

点赞

举报

评论

推荐
最新

empty

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":176065879,"tweetId":"176065879","gmtCreate":1626846675491,"gmtModify":1626846675491,"author":{"id":3560503026480162,"idStr":"3560503026480162","authorId":3560503026480162,"authorIdStr":"3560503026480162","name":"吴富暴富","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>呵呵</p></body></html>","htmlText":"<html><head></head><body><p>呵呵</p></body></html>","text":"呵呵","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/176065879","repostId":2153619495,"repostType":2,"repost":{"id":"2153619495","pubTimestamp":1626844415,"share":"https://www.laohu8.com/m/news/2153619495?lang=&edition=full","pubTime":"2021-07-21 13:13","market":"us","language":"zh","title":"高盛首予科济药业-B(02171.HK)「买入」评级  目标价48.72元","url":"https://stock-news.laohu8.com/highlight/detail?id=2153619495","media":"AAFN","summary":"高盛发表研究报告，首予科济药业-B  「买入」评级，目标价48.72元。该行称，公司是临床阶段生科企业，专注於实质固态瘤及血液科恶性疾病的创新嵌合抗原受体(CAR-T)细胞疗法。该行相信科济药业将是CAR-T行业领导，旗下CLDN 18.2-目标CAR-T CT041有潜在成为全球同类第一(FIC)，具良好胃癌早期临床数据；以及全球专利有重大海外商业机遇。(da/a)~阿思达克财经新闻网址: www.aastocks.com","content":"<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发表研究报告，首予<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>  「买入」评级，目标价48.72元。该行称，公司是临床阶段生科企业，专注於实质固态瘤及血液科恶性疾病的创新嵌合抗原受体(CAR-T)细胞疗法。该行相信科济药业将是CAR-T行业领导，旗下CLDN 18.2-目标CAR-T CT041有潜在成为全球同类第一(FIC)，具良好胃癌早期临床数据；以及全球专利有重大海外商业机遇。(da/a)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛首予科济药业-B(02171.HK)「买入」评级  目标价48.72元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛首予科济药业-B(02171.HK)「买入」评级  目标价48.72元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 13:13 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1114302&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表研究报告，首予科济药业-B  「买入」评级，目标价48.72元。该行称，公司是临床阶段生科企业，专注於实质固态瘤及血液科恶性疾病的创新嵌合抗原受体(CAR-T)细胞疗法。该行相信科济药业将是CAR-T行业领导，旗下CLDN 18.2-目标CAR-T CT041有潜在成为全球同类第一(FIC)，具良好胃癌早期临床数据；以及全球专利有重大海外商业机遇。(da/a)~阿思达克财经新闻网址: ...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1114302&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c4a03a5ae5cfc1aad727ce9e6d2b27bb","relate_stocks":{"02171":"科济药业-B"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1114302&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2153619495","content_text":"高盛发表研究报告，首予科济药业-B  「买入」评级，目标价48.72元。该行称，公司是临床阶段生科企业，专注於实质固态瘤及血液科恶性疾病的创新嵌合抗原受体(CAR-T)细胞疗法。该行相信科济药业将是CAR-T行业领导，旗下CLDN 18.2-目标CAR-T CT041有潜在成为全球同类第一(FIC)，具良好胃癌早期临床数据；以及全球专利有重大海外商业机遇。(da/a)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":868,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}